user
cart
menu
orderQuote Inquiry / OrdercartCart
letter
Sign InRegister
langEnglisharrow

Tau

Tau

Tau Overview

Molecule Name
Microtubule-associated protein tau
Synonyms
DDPAC,FTDP-17,MAPT,MSTD,MTBT1,Tau,PHF-tau,TAU
Drug Development Progress
Drugs in Clinical Trials45
Approved Drugs1
Highest Development StageApproved
Target Synonym
MAPT，MTBT1，Paired helical filament-tau，MAPTL，Microtubule Associated Protein Tau，G Protein Beta1/Gamma2 Subunit-Interacting Factor 1，Protein Phosphatase 1， Regulatory Subunit 103，Neurofibrillary Tangle Protein，PHF-Tau，TAU，Microtubule-Associated Protein Tau， Isoform 4，Microtubule-Associated Protein Tau，PPP1R103，FTDP-17，MTBT2，DDPAC，MSTD，PPND，tau Proteins，MGC138549，FLJ31424
Background
Tau, the microtubule‐associated protein, forms insoluble filaments that accumulate as neurofibrillary tangles in Alzheimer's disease (AD) and related tauopathies. Under physiological conditions, tau regulates the assembly and maintenance of the structural stability of microtubules. In the diseased brain, however, tau becomes abnormally hyperphosphorylated, which ultimately causes the microtubules to disassemble, and the free tau molecules aggregate into paired helical filaments.

Tau Product List

Species
  • Human（22）
  • Cynomolgus（1）
Tag
  • Tag Free（13）
  • His Tag（9）
  • His Tag & Avi Tag（1）
Host
  • E. coli（22）
  • Yeast（1）
Conjugate
  • Unconjugated（22）
  • Biotin-labeled（1）
Grade
  • RUO（23）
Low Endotoxin
  • Yes（11）
  • No（12）
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&PriceAdd to Cart
Tau
HOT
TAU-H5115
Human Tau-441 / 2N4R Pre-formed Fibrils Protein, Tag Free
Human
E. coli
SDS-PAGE
CELL BASEThT

$400.00

100ug
Tau
HOT
TAU-H5113
Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free
Human
E. coli
SDS-PAGE
CELL BASE

$375.00

100ug
Tau
HOT
TAU-H51H3
Human Tau-441 / 2N4R Protein, His Tag, low endotoxin
Human
E. coli
SDS-PAGE
ELISA

$305.00

100ug
Tau
HOT
TAU-H5117
Human Tau-441 / 2N4R Protein, Tag Free, low endotoxin (Mass Spec & MALS verified)
Human
E. coli
MALSSDS-PAGE
ELISAThT

$305.00

100ug
Tau
TAU-C5113
Cynomolgus Tau Protein, Tag Free, low endotoxin
Cynomolgus
Yeast
ELISA

$360.00

100ug
Tau
TAU-H5112
Human Tau-381 / 1N3R Protein, Tag Free, low endotoxin (MALS verified)
Human
E. coli
MALSSDS-PAGE
ELISA

$280.00

100ug
Tau
TAU-H5114
Human Tau Protein, Tag Free, low endotoxin (MALS verified)
Human
E. coli
MALSSDS-PAGE

$290.00

100ug
Tau
TAU-H5116
Human Tau-441 K18 Pre-formed Fibrils Protein, Tag Free
Human
E. coli
SDS-PAGE

$375.00

100ug
Tau
TAU-H5118
Human Tau-441 (K18, P301L) Protein, Tag Free, low endotoxin (MALS verified)
Human
E. coli
MALSSDS-PAGE

$290.00

100ug
Tau
TAU-H5119
Human Tau-412 / 1N4R Protein, Tag Free, low Endotoxin (MALS verified)
Human
E. coli
MALSSDS-PAGE
ELISA

$295.00

100ug
You Have Viewed 1-10 Of 23 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

Product InquiryRequest Customization
FAQ

How does the "Structure & Application Integrated" platform ensure the reliability of ACRO’s linker antibodies?

Every batch of our anti-linker antibodies undergoes rigorous validation, including SEC-HPLC for purity (typically >95%) and functional testing in flow cytometry using real transfected cell lines (e.g., HEK293T or CHO). This integrated approach ensures that the antibody recognizes the target in the context of a live cell membrane.

What storage conditions are recommended to maintain the long-term stability of the anti-linker antibody?

Anti linker antibodies are typically supplied as lyophilized powders. For long term storage, keep the lyophilized product at 20°C or lower, protected from light, and avoid repeated freeze thaw cycles. After reconstitution, store at 2 8°C for short term use, or aliquot and freeze at 20°C for long term storage.

Can this antibody be used to verify the expression of multi-specific or bispecific CARs?

If the bispecific CAR incorporates the 218 linker within its scFv components, the antibody will be able to detect its expression. This is particularly useful for verifying the surface density of complex, multi-targeting constructs where individual antigen-binding might be difficult to quantify.

Are these anti-linker antibodies compatible with next-generation "off-the-shelf" allogeneic therapies?

Yes. As researchers move toward CAR-NK and allogeneic iPSC-derived therapies, the 218 linker remains a standard structural component. ACRO’s universal detection tools are fully compatible with these platforms, providing a consistent way to verify engineering success across diverse cell types.

My CAR construct is prone to aggregation. How can I verify if the linker remains accessible for detection?

The 218 linker is specifically designed to reduce aggregation. If detection issues persist, it may indicate a deeper structural problem with the scFv folding. Using an anti-linker antibody in Simple Western™ or flow cytometry can help researchers determine if the linker is exposed and accessible, serving as a vital tool for structural troubleshooting.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
BuntanetapANVS-405; ANVS-401Phase 3 ClinicalRaptor Pharmaceutical
Alzheimer Disease; Chronic Traumatic Encephalopathy; Cognitive Dysfunction; Down Syndrome; Frontotemporal Dementia; Parkinson Disease
Details
FlorzolotauF0-PBB3; PM-PBB3; [18F]APN-1607; [18F]MNI-958; APN-0000455; [18F]PM-PBB3; APN-1607; 18F-PM-PBB3; 18F-APN-1607Phase 3 ClinicalAprinoia Therapeutics Ltd
Alzheimer Disease; Cognition Disorders; Cognitive Dysfunction; Diagnostic agents; Nerve Degeneration; Supranuclear Palsy, Progressive
Details
EtalanetugE-2814Phase 3 ClinicalEisai Co Ltd
Alzheimer Disease; Dementia
Details
Izaflortaucipir F-18PI-2620; 18F-PI-2620; [18F]PI-2620Phase 3 ClinicalAc Immune Sa, Piramal
Alzheimer Disease; Brain Injuries, Traumatic; Cognitive Dysfunction; Frontotemporal Lobar Degeneration; Opioid-Related Disorders; Parkinson Disease; Supranuclear Palsy, Progressive
Details
[F-18]Flornaptitril[F-18]FDDNP; F-18-FNT-PETPhase 3 ClinicalUniversity Of California At Los Angeles
Alzheimer Disease; Chronic Traumatic Encephalopathy
Details
XTR-006XTR-006Phase 3 ClinicalBeijing Xiantong International Technology Co Ltd
Alzheimer Disease; Tauopathies
Details
ZagotenemabLY-3303560Phase 2 ClinicalEli Lilly And Company
Alzheimer Disease
Details
PosdinemabJNJ-3657; JNJ-63733657Phase 2 ClinicalJohnson & Johnson Innovative Medicine
Alzheimer Disease; Cognitive Dysfunction; Dementia
Details
[18F]GTP-1[18F]GTP-1Phase 2 ClinicalGenentech Inc
Alzheimer Disease
Details
[18F]THK-5105[18F]THK-5105Phase 2 ClinicalTohoku University
Alzheimer Disease
Details
ISIS-814907BIIB-080; ISIS-814907; IONIS-MAPTRx; ISIS-BIIB4Rx; IONIS-BIIB4RXPhase 2 ClinicalBiogen Inc, Ionis Pharmaceuticals Inc
Alzheimer Disease; Cognitive Dysfunction
Details
TilavonemabC2N-8E12; ABBV-8E12Phase 2 ClinicalC2n Diagnostics Llc
Alzheimer Disease; Supranuclear Palsy, Progressive
Details
Alzheimer's disease vaccine (Axon Neuroscience)AADvac-1Phase 2 ClinicalAxon Biochemicals
Alzheimer Disease; Primary Progressive Nonfluent Aphasia; Supranuclear Palsy, Progressive
Details
SemorinemabMTAU-9937A; MTAU9937A; RG-6100; RO7105705; RO-7105705Phase 2 ClinicalAc Immune Sa
Alzheimer Disease
Details
APN-1701[18F]AM-PBB3; 18F-AM-PBB3; APN-1701Phase 2 ClinicalAprinoia Therapeutics Ltd, National Institute Of Radiological Sciences
Alzheimer Disease; Nerve Degeneration
Details
VY-TAU-01VY-TAU01; VY-TAU-01; VY-7523Phase 2 ClinicalVoyager Therapeutics Inc
Alzheimer Disease
Details
Anti-tau antibody (Prothena)BMS-986446; PRX-005Phase 2 ClinicalProthena
Alzheimer Disease; Frontotemporal Dementia
Details
MK-2214MK-2214Phase 2 ClinicalMerck Sharp & Dohme LLC
Alzheimer Disease
Details
BEY-2153BEY-2153Phase 2 ClinicalBeyondbio Inc
Alzheimer Disease
Details
BepranemabUCB-0107; RG6416Phase 2 ClinicalUcb
Alzheimer Disease; Supranuclear Palsy, Progressive
Details
[18F]THK-5117[18F]THK-5117Phase 2 ClinicalTohoku University
Alzheimer Disease
Details
PNT-001PNT-001Phase 1 ClinicalBeth Israel Deaconess Medical Center
Alzheimer Disease; Brain Injuries, Traumatic
Details
ReS19-TReS19-TPhase 1 ClinicalRemynd
Alzheimer Disease
Details
Mecripyrine HydrochlorideSCR-1693; Y-1A; Y-1Phase 1 ClinicalJiangsu Simcere Pharmaceutical Co Ltd, NeuroDawn Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd
Alzheimer Disease; Brain Neoplasms
Details
Lu-AF87908Lu-AF87908; Lu-AF-87908Phase 1 ClinicalH. Lundbeck A/S
Alzheimer Disease
Details
RDC-5RDC-5Phase 1 ClinicalChronos Therapeutics Ltd
Amyotrophic Lateral Sclerosis
Details
MC-1 (Lilly)MC-1 (Lilly)Phase 1 ClinicalEli Lilly And Company
Alzheimer Disease
Details
OLX-07010OLX07010Phase 1 ClinicalOligomerix Inc
Alzheimer Disease; Dementia; Neurodegenerative Diseases; Supranuclear Palsy, Progressive
Details
ProtollinPhase 1 ClinicalThe Brigham and Women's Hospital
Alzheimer Disease
Details
NB-02NB-02; DA-9803Phase 1 ClinicalDong-A ST Co Ltd
Alzheimer Disease; Lymphoma, Non-Hodgkin
Details
MAPT siRNA therapeutic (Eli Lilly and Company)Phase 1 ClinicalEli Lilly And Company
Neurodegenerative Diseases
Details
18F-JSS20-183A18F-JSS20-183APhase 1 ClinicalUniversity Of Pennsylvania
Tauopathies
Details
ATC-102ATC-102; ATC102Phase 1 ClinicalAutotac Bio Inc
Alzheimer Disease
Details
AB-19 (AUTOTAC Bio)AB-19 (AUTOTAC Bio)Phase 1 ClinicalAutotac Bio Inc
Supranuclear Palsy, Progressive
Details
AB-12 po (AUTOTAC Bio)AB-12 poPhase 1 ClinicalAutotac Bio Inc
Alzheimer Disease
Details
DNL-628OTV:MAPT; DNL-628Phase 1 ClinicalDenali Therapeutics Inc
Alzheimer Disease
Details
[89Zr]Zr-DFO-BIIB080[89Zr]Zr-DFO; [89Zr]Zr-DFO-ISIS-814907Phase 1 ClinicalBiogen Inc
Details
DA-7503DA-7503Phase 1 ClinicalDong-A ST Co Ltd
Details
LY-3954068LY3954068; LY-3954068Phase 1 ClinicalEli Lilly And Company
Alzheimer Disease
Details
AS-603S-603; AS-603; AS-S603Phase 1 ClinicalAmyloid Solution Inc
Alzheimer Disease
Details
ADEL-Y01ADEL-Y01Phase 1 ClinicalADEL Inc, Oscotec Inc
Alzheimer Disease; Tauopathies
Details
APNmAb-005APNmAb-005Phase 1 ClinicalAprinoia Therapeutics Ltd
Alzheimer Disease; Nerve Degeneration; Tauopathies
Details
AV-1959R/AV-1980R1959R + 1980R; AV 1959R + AV 1980RPhase 1 ClinicalNuravax
Alzheimer Disease
Details
NIO-752NIO-752Phase 1 ClinicalNovartis Pharma Ag
Alzheimer Disease; Cognitive Dysfunction; Neurodegenerative Diseases; Supranuclear Palsy, Progressive
Details
11C-PBB311C-PBB3ClinicalNational Institute Of Radiological Sciences
Alzheimer Disease
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Flortaucipir F1818F-AV-1451; T807; F-18-AV-1451; [18F]-T-807; [3H]AV 1451; [F-18]T807; [F18]AV1451; LY3191748ApprovedSiemens Medical SolutionTauvidUnited StatesAlzheimer DiseaseAvid Radiopharmaceuticals Inc2020-05-28
Alzheimer Disease; Aphasia, Primary Progressive; Brain Concussion; Brain Injuries; Brain Injuries, Traumatic; Chronic Traumatic Encephalopathy; Cognition Disorders; Cognitive Dysfunction; Corticobasal degeneration; Dementia; Depression; Diagnostic agents; Frontotemporal Dementia; Neurodegenerative Diseases; Parkinson Disease; Pick Disease of the Brain; Supranuclear Palsy, Progressive; Tauopathies
Details
Customer Reviews
  • P***g2021-08-24
    Human Tau-441 / 2N4R Protein, His Tag, low endotoxin
    I have purchased multiple antigens from ACRO for discovery projects and I have found that the quality of antigens purchased from Acro is great!! Acro has become by go to vendor when I am looking for quality antigens. In addition, Acro also provides an impressive range of formats for each antigens, including different tags. Not to mention, their customer service team is fantastic. Overall, a great company to work with.